1228. Deputy Barry Ward asked the Minister for Health the position regarding the approvement process for a drug (details supplied) for the treatment of bronchiectasis; and if she will make a statement on the matter. [37704/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions under the heading Medicinal Products.
1,228 questions match, newest first.
1229. Deputy Barry Ward asked the Minister for Health the position regarding a timeline for the approval for a drug (details supplied) for the treatment of bronchiectasis; and if she will make a statement on the matter. [37705/26]
1230. Deputy Barry Ward asked the Minister for Health the position regarding any engagement she has had with the HPRA in relation to the approval for a drug (details supplied) for the treatment of bronchiectasis; and if she will make a statement on the matter. [37706/26]
1231. Deputy Barry Ward asked the Minister for Health if she will set out the mechanism and timeframe of reference for the HPRA to approve the use of a particular pharmaceutical; and if she will make a statement on the matter. [37707/26]
519. Deputy Brian Stanley asked the Minister for Health if melatonin and magnesium preparations are currently covered under the long-term illness scheme; if they were previously included; if so, the date and basis on which they were removed; and if she will make a statement on the matter. [35829/26]
520. Deputy Brian Stanley asked the Minister for Health if she will undertake a review of the clinical and policy basis for excluding melatonin and magnesium from the long-term illness scheme; and if she will consider reinstating these medications to the approved list; and if she will make a statement on the matter. [35830/26]
521. Deputy Brian Stanley asked the Minister for Health if her Department has assessed the impact on patients, particularly those with neurological, developmental, or sleep-related conditions, of melatonin and magnesium not being covered under the long-term illness scheme; and if she will make a statement on the matter. [35831/26]
536. Deputy Robert O'Donoghue asked the Minister for Health if she will outline the pathway available for access to the medication Miglustat for a child diagnosed with Juvenile Batten Disease (CLN3), where the medication is already approved and reimbursed in Ireland for other rare conditions, including Gaucher Disease and Niemann-Pick Type C; and if she will make a statement on the matter. [35902/26]
538. Deputy Robert O'Donoghue asked the Minister for Health if she will review the case for access to Miglustat for children diagnosed with Juvenile Batten Disease, particularly where there is significant unmet clinical need and no alternative treatment currently available; and if she will make a statement on the matter. [35904/26]
540. Deputy Mark Wall asked the Minister for Health if she will consider including fibromyalgia in the long-term illness scheme; and if she will make a statement on the matter. [35908/26]
546. Deputy Pearse Doherty asked the Minister for Health if she will intervene to make the drug Givinostat available to children who need it, given that parents of a child that suffers from Duchenne muscular dystrophy has recently made a public plea for the drug to be made available urgently; and if she will make a statement on the matter. [35938/26]
562. Deputy Ken O'Flynn asked the Minister for Health the total expenditure by the HSE in each of the years on the reimbursement of medicines prescribed for erectile dysfunction, including sildenafil and tadalafil; medicines prescribed for menopause-related conditions, including hormone replacement therapy products and topical vaginal oestrogen preparations, under the general medical services scheme, the drugs paymen…
773. Deputy Ken O'Flynn asked the Minister for Health whether dispensing trends for salbutamol nebules are monitored as part of winter preparedness or respiratory surveillance planning. [36448/26]
774. Deputy Ken O'Flynn asked the Minister for Health whether the HSE maintains regional prescribing trend analysis for nebulised bronchodilator medications; and if so, to provide the latest available data. [36449/26]
775. Deputy Ken O'Flynn asked the Minister for Health whether any review has been undertaken into the drivers of variation in average reimbursement cost per salbutamol nebule item under the General Medical Services scheme since 2024. [36450/26]
777. Deputy Ken O'Flynn asked the Minister for Health whether the Department has assessed the extent to which high-frequency salbutamol dispensing may indicate gaps in preventative asthma or COPD management in primary care. [36452/26]
778. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has identified any supply-chain, pricing or reimbursement pressures affecting nebulised respiratory medications since 2024. [36453/26]
781. Deputy John Lahart asked the Minister for Health the specific steps being taken to ensure the HSE considers the "time-critical" nature of Friederichs Ataxia during the current price negotiations for Skyclarys; the way in which the commitments in the National Rare Disease Strategy 2025-2030 and the 2026 IPHA Framework Agreement (which aims for a 180-day decision timeline) are being applied to this specific case, …
231. Deputy Pearse Doherty asked the Minister for Health when a decision will be made on the availability and funding of givinostat for Duchenne muscular dystrophy; and if she will make a statement on the matter. [35421/26]
1019. Deputy Donna McGettigan asked the Minister for Health to ensure a person (details supplied) will receive a discretionary hardship payment as an interim support, pending the outcome of the acarizax reimbursement application due to significant financial hardship and the medical necessity of the treatment; and if she will make a statement on the matter. [33989/26]
1191. Deputy Mary Lou McDonald asked the Minister for Health the position in relation to the approval of the drug ryeqo which is used in other jurisdictions in the treatment of endometriosis; and if she will make a statement on the matter. [35037/26]
1215. Deputy Pádraig O'Sullivan asked the Minister for Health if she will outline what steps her Department is taking to address the fact that brexpiprazole and lurasidone, two antipsychotic medicines now recommended as first-line treatment options for females with first-episode psychosis in the first international clinical guideline of its kind published in March 2026, are currently licensed in Ireland but not reimb…
1217. Deputy Pádraig Rice asked the Minister for Health the reason that a supplement (details supplied) has not been made available under the drugs payment scheme; the actions necessary for this supplement to be made eligible for reimbursement under the scheme; and if she will make a statement on the matter. [35192/26]
1240. Deputy Colm Burke asked the Minister for Health whether she is concerned about the promotion and sale of obesity medicines to under-18s for cosmetic weight-loss purposes by black-market actors; and if she will make a statement on the matter. [35309/26]
476. Deputy Gillian Toole asked the Minister for Health if information (details supplied) in relation to a series of matters regarding the policy, clinical and financial rationale for restricting access to long-acting injectable buprenorphine will be provided; and if she will make a statement on the matter. [33481/26]